Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34 kDa rhoptry antigen (Pv34)

This study describes the identification of the Plasmodium vivax rhoptry antigen Pv34 whose sequence was obtained based on homology comparison with the Plasmodium falciparum Pf34. The pv34 gene product was characterized by molecular biology and immunological techniques. Additionally, association of P...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:: 2009

Institución:: Universidad del Rosario

Repositorio:: Repositorio EdocUR - U. Rosario

Idioma:: eng

id	EDOCUR2_ed3f1ea096ef4f74b026cd2a7bbf50f6
oai_identifier_str	oai:repository.urosario.edu.co:10336/23457
network_acronym_str	EDOCUR2
network_name_str	Repositorio EdocUR - U. Rosario
repository_id_str
spelling	914e954b-fc69-43d1-8b0b-ddda45ad991a-170b2cbbb-5646-444b-90be-0a9c18f31ba8-10c7f05bb-7732-4053-bac4-7444b92057c5-16fc431a4-2889-4e78-ba01-10c2807c6557-11609eecf-af24-4e1e-9f07-4f944f55908f-1fe062efa-2c45-40ad-9076-805a8d1e00ac-179653065-12020-05-26T00:02:11Z2020-05-26T00:02:11Z2009This study describes the identification of the Plasmodium vivax rhoptry antigen Pv34 whose sequence was obtained based on homology comparison with the Plasmodium falciparum Pf34. The pv34 gene product was characterized by molecular biology and immunological techniques. Additionally, association of Pv34 to detergent-resistant microdomains (DRMs), expression in late blood-stage parasites and recognition of recombinant Pv34 (rPv34) by sera from P. vivax-infected Aotus monkeys and patients was assessed. Lymphoproliferation and cytokine secretion was also evaluated in individuals living in malaria endemic areas. Altogether, the data support carrying out further studies to assess the immunogenicity and protection-inducing ability of rPv34 as component of a multi-antigenic, multi-stage vaccine against vivax malaria. © 2009 Elsevier Ltd. All rights reserved.application/pdfhttps://doi.org/10.1016/j.vaccine.2009.10.0340264410X13588745https://repository.urosario.edu.co/handle/10336/23457eng421No. 2415VaccineVol. 28Vaccine, ISSN:0264410X, 13588745, Vol.28, No.2 (2009); pp. 415-421https://www.scopus.com/inward/record.uri?eid=2-s2.0-70649093849&doi=10.1016%2fj.vaccine.2009.10.034&partnerID=40&md5=a74ebb3c1ffe22e37c9bd7bf88dba4c0Abierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURChloroquineGamma interferonInterleukin 10Interleukin 2Interleukin 4Interleukin 5Malaria vaccinePrimaquineRecombinant plasmodium vivax 34 antigenRecombinant proteinTumor necrosis factor alphaUnclassified drugAnimal experimentArticleBlood samplingCytokine releaseDrug antigenicityHumanHumoral immunityImmunogenicityLymphocyte proliferationMolecular biologyMonkeyNonhumanNucleotide sequencePeripheral blood mononuclear cellPlasmodium vivaxPlasmodium vivax malariaPriority journalProtein blood levelRabbitAdultAgedAnimalsCytokinesHaplorhiniHumansMalaria vaccinesMiddle agedPlasmodium vivaxProtozoan proteinsRabbitsPf34 homologuePlasmodium vivaxVaccine candidateindirectpolyacrylamide gelwesternBlottingElectrophoresisFluorescent antibody techniqueCharacterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34 kDa rhoptry antigen (Pv34)articleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Mongui, AlvaroAngel, Diana I.Gallego, GinaReyes, ClaudiaMartinez, PaolaGuhl, FelipePatarroyo, Manuel A.ORIGINALCharacterization_and_antigenicity_of_the.pdfapplication/pdf4380060https://repository.urosario.edu.co/bitstreams/9dd5eddb-b2e9-402f-91a1-4ebf144a4e4f/download086c270ff3da07b80158b4db6d814be0MD51TEXTCharacterization_and_antigenicity_of_the.pdf.txtCharacterization_and_antigenicity_of_the.pdf.txtExtracted texttext/plain46433https://repository.urosario.edu.co/bitstreams/377c6fef-ac31-47de-af30-f6cdda2d1db3/download232fade38ba978b475eea35dafb05d96MD52THUMBNAILCharacterization_and_antigenicity_of_the.pdf.jpgCharacterization_and_antigenicity_of_the.pdf.jpgGenerated Thumbnailimage/jpeg4767https://repository.urosario.edu.co/bitstreams/4f9ff9d8-d4bd-4aec-bd4f-8b4847908bc5/download87c29c5b828fb954d2afc7b9d0cd20eaMD5310336/23457oai:repository.urosario.edu.co:10336/234572022-05-02 07:37:20.977537https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co
dc.title.spa.fl_str_mv	Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34 kDa rhoptry antigen (Pv34)
title	Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34 kDa rhoptry antigen (Pv34)
spellingShingle	Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34 kDa rhoptry antigen (Pv34) Chloroquine Gamma interferon Interleukin 10 Interleukin 2 Interleukin 4 Interleukin 5 Malaria vaccine Primaquine Recombinant plasmodium vivax 34 antigen Recombinant protein Tumor necrosis factor alpha Unclassified drug Animal experiment Article Blood sampling Cytokine release Drug antigenicity Human Humoral immunity Immunogenicity Lymphocyte proliferation Molecular biology Monkey Nonhuman Nucleotide sequence Peripheral blood mononuclear cell Plasmodium vivax Plasmodium vivax malaria Priority journal Protein blood level Rabbit Adult Aged Animals Cytokines Haplorhini Humans Malaria vaccines Middle aged Plasmodium vivax Protozoan proteins Rabbits Pf34 homologue Plasmodium vivax Vaccine candidate indirect polyacrylamide gel western Blotting Electrophoresis Fluorescent antibody technique
title_short	Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34 kDa rhoptry antigen (Pv34)
title_full	Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34 kDa rhoptry antigen (Pv34)
title_fullStr	Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34 kDa rhoptry antigen (Pv34)
title_full_unstemmed	Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34 kDa rhoptry antigen (Pv34)
title_sort	Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34 kDa rhoptry antigen (Pv34)
dc.subject.keyword.spa.fl_str_mv	Chloroquine Gamma interferon Interleukin 10 Interleukin 2 Interleukin 4 Interleukin 5 Malaria vaccine Primaquine Recombinant plasmodium vivax 34 antigen Recombinant protein Tumor necrosis factor alpha Unclassified drug Animal experiment Article Blood sampling Cytokine release Drug antigenicity Human Humoral immunity Immunogenicity Lymphocyte proliferation Molecular biology Monkey Nonhuman Nucleotide sequence Peripheral blood mononuclear cell Plasmodium vivax Plasmodium vivax malaria Priority journal Protein blood level Rabbit Adult Aged Animals Cytokines Haplorhini Humans Malaria vaccines Middle aged Plasmodium vivax Protozoan proteins Rabbits Pf34 homologue Plasmodium vivax Vaccine candidate
topic	Chloroquine Gamma interferon Interleukin 10 Interleukin 2 Interleukin 4 Interleukin 5 Malaria vaccine Primaquine Recombinant plasmodium vivax 34 antigen Recombinant protein Tumor necrosis factor alpha Unclassified drug Animal experiment Article Blood sampling Cytokine release Drug antigenicity Human Humoral immunity Immunogenicity Lymphocyte proliferation Molecular biology Monkey Nonhuman Nucleotide sequence Peripheral blood mononuclear cell Plasmodium vivax Plasmodium vivax malaria Priority journal Protein blood level Rabbit Adult Aged Animals Cytokines Haplorhini Humans Malaria vaccines Middle aged Plasmodium vivax Protozoan proteins Rabbits Pf34 homologue Plasmodium vivax Vaccine candidate indirect polyacrylamide gel western Blotting Electrophoresis Fluorescent antibody technique
dc.subject.keyword.eng.fl_str_mv	indirect polyacrylamide gel western Blotting Electrophoresis Fluorescent antibody technique
description	This study describes the identification of the Plasmodium vivax rhoptry antigen Pv34 whose sequence was obtained based on homology comparison with the Plasmodium falciparum Pf34. The pv34 gene product was characterized by molecular biology and immunological techniques. Additionally, association of Pv34 to detergent-resistant microdomains (DRMs), expression in late blood-stage parasites and recognition of recombinant Pv34 (rPv34) by sera from P. vivax-infected Aotus monkeys and patients was assessed. Lymphoproliferation and cytokine secretion was also evaluated in individuals living in malaria endemic areas. Altogether, the data support carrying out further studies to assess the immunogenicity and protection-inducing ability of rPv34 as component of a multi-antigenic, multi-stage vaccine against vivax malaria. © 2009 Elsevier Ltd. All rights reserved.
publishDate	2009
dc.date.created.spa.fl_str_mv	2009
dc.date.accessioned.none.fl_str_mv	2020-05-26T00:02:11Z
dc.date.available.none.fl_str_mv	2020-05-26T00:02:11Z
dc.type.eng.fl_str_mv	article
dc.type.coarversion.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv	Artículo
dc.identifier.doi.none.fl_str_mv	https://doi.org/10.1016/j.vaccine.2009.10.034
dc.identifier.issn.none.fl_str_mv	0264410X 13588745
dc.identifier.uri.none.fl_str_mv	https://repository.urosario.edu.co/handle/10336/23457
url	https://doi.org/10.1016/j.vaccine.2009.10.034 https://repository.urosario.edu.co/handle/10336/23457
identifier_str_mv	0264410X 13588745
dc.language.iso.spa.fl_str_mv	eng
language	eng
dc.relation.citationEndPage.none.fl_str_mv	421
dc.relation.citationIssue.none.fl_str_mv	No. 2
dc.relation.citationStartPage.none.fl_str_mv	415
dc.relation.citationTitle.none.fl_str_mv	Vaccine
dc.relation.citationVolume.none.fl_str_mv	Vol. 28
dc.relation.ispartof.spa.fl_str_mv	Vaccine, ISSN:0264410X, 13588745, Vol.28, No.2 (2009); pp. 415-421
dc.relation.uri.spa.fl_str_mv	https://www.scopus.com/inward/record.uri?eid=2-s2.0-70649093849&doi=10.1016%2fj.vaccine.2009.10.034&partnerID=40&md5=a74ebb3c1ffe22e37c9bd7bf88dba4c0
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.acceso.spa.fl_str_mv	Abierto (Texto Completo)
rights_invalid_str_mv	Abierto (Texto Completo) http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.none.fl_str_mv	application/pdf
institution	Universidad del Rosario
dc.source.instname.spa.fl_str_mv	instname:Universidad del Rosario
dc.source.reponame.spa.fl_str_mv	reponame:Repositorio Institucional EdocUR
bitstream.url.fl_str_mv	https://repository.urosario.edu.co/bitstreams/9dd5eddb-b2e9-402f-91a1-4ebf144a4e4f/download https://repository.urosario.edu.co/bitstreams/377c6fef-ac31-47de-af30-f6cdda2d1db3/download https://repository.urosario.edu.co/bitstreams/4f9ff9d8-d4bd-4aec-bd4f-8b4847908bc5/download
bitstream.checksum.fl_str_mv	086c270ff3da07b80158b4db6d814be0 232fade38ba978b475eea35dafb05d96 87c29c5b828fb954d2afc7b9d0cd20ea
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5
repository.name.fl_str_mv	Repositorio institucional EdocUR
repository.mail.fl_str_mv	edocur@urosario.edu.co
_version_	1831928320362545152

Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34 kDa rhoptry antigen (Pv34)

Publicaciones similares